中药治疗原发性肝癌Ⅲ期围手术期患者42例  

Effect of Chinese Herbal Medicine on Patients with Primary Hepatic Carcinoma in Ⅲ Stage During Perioperational Period : A Report of 42 Cases

作　　者：陈立武[1] 林晶[1] 陈文[1] 张伟平[1] 

机构地区：[1]福建省第二人民医院肿瘤科,福州350003

出　　处：《中国中西医结合杂志》2005年第9期832-834,共3页Chinese Journal of Integrated Traditional and Western Medicine

摘　　要：目的观察中药治疗与手术相结合对原发性肝癌Ⅲ期患者的协同作用。方法综合组42例在手术前7天口服中药解毒消饮并于术后7天继续口服扶正抑瘤方2年,对照组30例只作单纯手术,比较两组手术前后细胞免疫功能、手术后的生存率及复发情况。结果综合组术后4、8周NK细胞活性及CD4+/CD8与对照组比较,差异有显著性(P<0.01)。综合组6、12、24及36个月累计生存率分别为97.6%(41/42例)、85.7%(36/42例)、52.3%(22/42例)、40.5%(17/42例),而对照组依次为96.7%(29/30例)、83.3%(25/30例)、50.0%(15/30例)、30.0%(9/30例),其中两组36个月生存率比较差异有显著性(P<0.05)。两组24个月复发率比较(综合组:54.8%,对照组:80.0%),差异有显著性(P<0.05)。结论复方中药在肝癌Ⅲ期围手术期中应用有明显作用,能够改善免疫功能、降低复发率及提高累计生存率。Objective To investigate the synergetic effect of general therapy of Chinese herbal medicine with surgical operation. Methods Fourty-two patients in the integrative group were treated with Jiedu Xiaozheng Yin for 7 days before operation, and Fuzheng Yiliu Recipe after operation for 2 years, and 30 patients in the control group underwent operation alone. Their cellular immune function, survival rate and recurrence rate were compared and analyzed. Results The accumulative survival rate of 6-month, 12-month, 24-month and 36-month in the integrative group was 97.6% （41/42）, 85.7% （36/42）, 52.3% （22/42） and 45.5（17/42） % respectively and those in the control group 96.7% （29/30）, 83.3% （25/30）, 50.0% （15/30） and 30.0% （9/ 30）, respectively, among them the 36-month survival rate was significantly different between the two groups （P〈0.05）. The24-month recurrence rate in the two groups was 54.8% and 80.0% respectively, the difference between the two was significant （P 〈 0.05）. Conclusion Administration of compound Ch medicine in peri-operational period has definite effect on primary hepatic carcinoma in Ⅲ stage, it patients＇ immune function, decrease the recurrence rate and increase the cumulative survival rate. inese herbal can improve

关 键 词：中药 手术 原发性肝癌 围手术期 中药治疗 Ⅲ期 患者 细胞免疫功能 NK细胞活性 口服中药 

分 类 号：R273[医药卫生—中西医结合]